Abstract

This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Highly active antiretroviral therapy (HAART) frequently results in body fat redistribution, dyslipidemia, and insulin resistance. Our previous studies in patients with HAART-induced metabolic syndrome showed that: 1) Pioglitazone administration over 12 months alters insulin resistance, blood pressure and lipid profile favorably, 2) R-metHuLeptin replacement at physiologic doses improves insulin resistance in HAART-induced lipoatrophy. The objective of this study is to evaluate whether pioglitazone and/or leptin are effective and safe for the treatment of HAART-induced lipatrophy and whether the combination of leptin and pioglitazone has an additive or multiplicative effect on insulin resistance, hyperlipidemia, body composition and cardiovascular risk factors in HAART-induced lipatrophy. This is a randomized, double-blind, placebo-controlled trial of HIV-infected patients with HAART-induced lipoatrophy.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR001032-33
Application #
7718908
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2008-04-01
Project End
2008-05-31
Budget Start
2008-04-01
Budget End
2008-05-31
Support Year
33
Fiscal Year
2008
Total Cost
$9,356
Indirect Cost

  Institution

Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code

  Publications

Nowak, Kristen L; You, Zhiying; Gitomer, Berenice et al. (2018) Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 29:571-578
Chung, Chen-Chih; Pimentel Maldonado, Daniela A; Jor'dan, Azizah J et al. (2018) Lower cerebral vasoreactivity as a predictor of gait speed decline in type 2 diabetes mellitus. J Neurol 265:2267-2276
Kline, Emily R; Seidman, Larry J; Cornblatt, Barbara A et al. (2018) Depression and clinical high-risk states: Baseline presentation of depressed vs. non-depressed participants in the NAPLS-2 cohort. Schizophr Res 192:357-363
Simpson, Norah S; Scott-Sutherland, Jennifer; Gautam, Shiva et al. (2018) Chronic exposure to insufficient sleep alters processes of pain habituation and sensitization. Pain 159:33-40
Dai, Weiying; Duan, Wenna; Alfaro, Freddy J et al. (2017) The resting perfusion pattern associates with functional decline in type 2 diabetes. Neurobiol Aging 60:192-202
Brosnahan, Godela M; Abebe, Kaleab Z; Rahbari-Oskoui, Frederic F et al. (2017) Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials. Curr Hypertens Rev 13:109-120
Torres, Vicente E; Abebe, Kaleab Z; Schrier, Robert W et al. (2017) Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int 91:493-500
Irazabal, María V; Abebe, Kaleab Z; Bae, Kyongtae Ty et al. (2017) Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrol Dial Transplant 32:1857-1865
Hart, Joseph; Novak, Vera; Saunders, Charles et al. (2016) Transcranial Doppler-Based Surrogates for Cerebral Blood Flow: A Statistical Study. PLoS One 11:e0165536
Alfaro, Freddy J; Lioutas, Vasileios-Arsenios; Pimentel, Daniela A et al. (2016) Cognitive decline in metabolic syndrome is linked to microstructural white matter abnormalities. J Neurol 263:2505-2514

Showing the most recent 10 out of 642 publications